Share: Facebook Twitter LinkedIn
Activity Provided By:


The Safety of Opioid Use in Chronic Obstructive Pulmonary Disease

Access Activity

Overview / Abstract:

This session will evaluate the safety of opioid therapy among patients with chronic obstructive pulmonary disease (COPD). The session will cover existing safety and effectiveness evidence from clinical trials, and present the latest data from observational studies. The presentation will include a discussion of the strengths and disadvantages of observational study designs along with implications for future practice.

Approximately 15.7 million Americans (6.4%) currently are diagnosed with COPD. Patients with COPD are prone to repeated exacerbations, which affect lung functioning, leading to increased risk for death, increased health care use and costs, and reduced quality of life. Current Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for the treatment of COPD recommend the use of opioids for the amelioration of breathlessness or dyspnea among patients with COPD but acknowledges the lack of adequate evidence supporting such treatment decisions. Existing clinical trials examining the effect of opioid use in severe COPD were conducted in small populations and either do not examine or do not find any concerning adverse effects. Rong et al., 2019 helps cover some of these gaps in knowledge.


May 12, 2024


Pharmacy CPE


Online, Webinar / Webcast / Video



Credits / Hours




Presenters / Authors / Faculty

Sujith Ramachandran, PhD
Assistant Professor
University of Mississippi School of Pharmacy

Keywords / Search Terms

CEimpact CEimpact, CE, opioids, journal club, adverse drug reactions, chronic obstructive pulmonary disorder

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map